Biomimetic HA-Binding Peptide Platform

The first HA-binding peptide platform built for cosmetic formulation

Biomimetic peptides that bind and stabilize hyaluronic acid through a gel-forming mechanism, slowing its enzymatic breakdown. Developed at Northwestern, refined for cosmetic use at the University of Arizona, and exclusively licensed worldwide.

Request the Technical Dossier Partnership Inquiry
Mechanism
RHAMM-inspired HA binding
License
Exclusive, worldwide · UA24-292
Structure
Delaware C-Corp
INCI
In progressfiling ~Q4 2026
Mechanism
HA bindingRHAMM-inspired
In-vitro
Visible HA gelcomplex formation
pH compatibility
Validation pending
Human efficacy
Ex-vivoexpected H1 2027
01 Market Opportunity

A large HA category, and the peptides that bind it are new

Peptide actives are a growing cosmetic ingredient category, and hyaluronic acid is among the most-used ingredients in skincare. We supply the actives that bind and stabilize HA, formulated into the formats that drive premium skincare: facial serums, moisturizers, and masks.

$16.8B
Global Market: Our 3 Formats
Facial serums, moisturizers, and masks worldwide (2025). The formats we supply into.
Mordor; Fortune; Straits
$4.5B
US Serviceable Market
The same three formats in the US; prestige beachhead ≈ $1.2B.
Grand View; Circana
$90–225M
Serviceable Obtainable Market
US retail carrying our ingredient at 2–5% of the US market.
Hyapeptides analysis · Unit Economics v12
$259→434M
Cosmetic Peptide Actives
The active-ingredient category we sell into, 2025 → 2035.
Persistence Market Research; Future Market Insights
02 The Technology

Biomimetic Peptide Platform

Developed at Northwestern and refined for cosmetic use at the University of Arizona. Exclusively licensed worldwide, with mechanism-of-action data from day one.

01 Bind
Peptide engages the HA chain.
02 Stabilize
Gel network forms and holds water.
03 Protect
Slows hyaluronidase breakdown.
Mechanism (in-vitro). The peptide binds and stabilizes hyaluronic acid, forming a gel network that slows enzymatic degradation. Peer-reviewed support: Acta Biomaterialia (2023); Science Progress (2024).
01
Advanced Hydration Support
Binds and stabilizes hyaluronic acid and protects it against enzymatic degradation through a gel-forming mechanism.
02
Formulation-Matched Customization
The platform is tailored to your formulation. Peptide and carrier are selected to suit your product matrix and amplify its existing benefits.
03
Mechanism-of-Action Dossier
Each ingredient ships with RHAMM-pathway binding data and regulatory documentation. This is the ingredient-level evidence that tightening EU and global rules now require.
Request the Technical One-Pager
03 Traction

Commercial engagement, ahead of efficacy data

Interest is already concrete, gated on the human efficacy data this round funds. Company and partner names are withheld here, and available under NDA.

40+
Qualified Leads
Active pipeline generated at in-cosmetics Global 2026 (Paris).
~18
Countries
Geographic spread of qualified inbound and conversations.
28
Technical Conversations
On-site technical or commercial dialogue at the show.
2
Peer-Reviewed Papers
Acta Biomaterialia (2023); Science Progress (2024).
04 IP & Partnership

How We Partner

We are the first to bring an HA-binding peptide platform to the cosmetic ingredient market. Early partners secure exclusive formulation positioning ahead of the category.

Intellectual Property
Exclusive Worldwide License
Exclusively licensed worldwide from the University of Arizona (UA24-292), all fields. University spin-off with mechanism-of-action data from day one.
Partnership Model
Turnkey Ingredient
Active ingredients designed to drop into your products, shipping with CMC, quality, and regulatory documentation in development.
Partnership Model
Tailored Co-Development
Peptide selection and formulation protocols tailored to your product line, scoped to your market segment.
Stage
Pre-Seed Round Open
Convertible note. Pre-clinical data and technical dossier available under NDA. Actively seeking co-development partners and early adopters.
Partnership Inquiry Investor Brief (under NDA)
05 FAQ

Frequently asked questions

A peptide engineered to bind and stabilize hyaluronic acid (HA) directly within a formulation. Hyapeptides' peptides mimic the natural RHAMM HA-binding mechanism. They engage the HA chain and form a gel network that slows enzymatic (hyaluronidase) degradation.

Most peptide and HA products co-formulate independent peptides alongside HA, where the components act separately. Hyapeptides' peptides physically bind and stabilize the HA itself through an RHAMM-inspired mechanism. We compete on mechanism, not on a blend.

The technology is exclusively licensed worldwide from the University of Arizona, across all fields of use.

In-vitro, our peptides form a visible HA gel/complex, demonstrating binding. We hold additional unpublished in-silico and in-vitro data. The approach has peer-reviewed support (Acta Biomaterialia, 2023; Science Progress, 2024). Human ex-vivo efficacy and safety testing is underway, with results expected around the end of 2026. Detailed data is available to partners under NDA.

We offer two models. The first is a turnkey active ingredient designed to drop into your products, with CMC, quality, and regulatory documentation. The second is tailored co-development, where peptide selection and formulation are scoped to your product line. To start, contact partnerships@hyapeptides.com.